These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9545990)

  • 1. Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects.
    Schlaepfer TE; Strain EC; Greenberg BD; Preston KL; Lancaster E; Bigelow GE; Barta PE; Pearlson GD
    Am J Psychiatry; 1998 Apr; 155(4):470-3. PubMed ID: 9545990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.
    Walsh SL; Strain EC; Abreu ME; Bigelow GE
    Psychopharmacology (Berl); 2001 Sep; 157(2):151-62. PubMed ID: 11594439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine.
    Greenwald MK; Stitzer ML
    Drug Alcohol Depend; 1998 Dec; 53(1):17-30. PubMed ID: 10933337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
    Walsh SL; Chausmer AE; Strain EC; Bigelow GE
    Psychopharmacology (Berl); 2008 Jan; 196(1):143-55. PubMed ID: 17909753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure.
    Jones HE; Bigelow GE; Preston KL
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1350-61. PubMed ID: 10336526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.
    Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Apr; 261(1):62-71. PubMed ID: 1373189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 2000 Oct; 295(1):114-24. PubMed ID: 10991968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute ethanol-induced changes in cerebral blood flow.
    Tiihonen J; Kuikka J; Hakola P; Paanila J; Airaksinen J; Eronen M; Hallikainen T
    Am J Psychiatry; 1994 Oct; 151(10):1505-8. PubMed ID: 8092344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discrimination in human post-addicts: agonist/antagonist opioids.
    Preston K; Bigelow G; Bickel W; Liebson I
    NIDA Res Monogr; 1988; 81():209-15. PubMed ID: 2457160
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.
    Preston KL; Bigelow GE
    J Pharmacol Exp Ther; 1994 Oct; 271(1):48-60. PubMed ID: 7525929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional cerebral blood flow changes in chronic alcoholic patients induced by naltrexone challenge during detoxification.
    Catafau AM; Etcheberrigaray A; Perez de los Cobos J; Estorch M; Guardia J; Flotats A; Bernà L; Marí C; Casas M; Carrió I
    J Nucl Med; 1999 Jan; 40(1):19-24. PubMed ID: 9935051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid antagonist effects of dezocine in opioid-dependent humans.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    Clin Pharmacol Ther; 1996 Aug; 60(2):206-17. PubMed ID: 8823239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug discrimination in human postaddicts: agonist-antagonist opioids.
    Preston KL; Bigelow GE; Bickel WK; Liebson IA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):184-96. PubMed ID: 2473187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technetium-99m-HMPAO, technetium-99m-ECD and iodine-123-IMP cerebral blood flow measurements with pharmacological interventions in primates.
    Dormehl IC; Oliver DW; Langen KJ; Hugo N; Croft SA
    J Nucl Med; 1997 Dec; 38(12):1897-901. PubMed ID: 9430465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral blood flow effects of acute intravenous heroin administration.
    Kosel M; Noss RS; Hämmig R; Wielepp P; Bundeli P; Heidbreder R; Kinser JA; Brenneisen R; Fisch HU; Kayser S; Schlaepfer TE
    Eur Neuropsychopharmacol; 2008 Apr; 18(4):278-85. PubMed ID: 18207374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers.
    Benkelfat C; Bradwejn J; Meyer E; Ellenbogen M; Milot S; Gjedde A; Evans A
    Am J Psychiatry; 1995 Aug; 152(8):1180-4. PubMed ID: 7625467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofrontality and negative symptoms in major depressive disorder.
    Galynker II; Cai J; Ongseng F; Finestone H; Dutta E; Serseni D
    J Nucl Med; 1998 Apr; 39(4):608-12. PubMed ID: 9544664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kappa opioid effect: increased urination in the rat.
    Leander JD
    J Pharmacol Exp Ther; 1983 Jan; 224(1):89-94. PubMed ID: 6294284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
    Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
    J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.